6 years of historical data (2019–2024) · Healthcare · Medical - Care Facilities
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
DocGo Inc. trades at 4.0x earnings, 90% below its 5-year average of 42.0x, sitting at the 0th percentile of its historical range. Compared to the Healthcare sector median P/E of 23.7x, the stock trades at a discount of 83%. On a free-cash-flow basis, the stock trades at 1.1x P/FCF, 94% below the 5-year average of 19.2x.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Market Cap | $73M | $464M | $590M | $728M | $887M | $1.0B | — |
| Enterprise Value | $41M | $432M | $578M | $591M | $728M | $999M | — |
| P/E Ratio → | 3.99 | 23.56 | 86.13 | 20.79 | 37.40 | — | — |
| P/S Ratio | 0.12 | 0.75 | 0.95 | 1.65 | 2.78 | 10.81 | — |
| P/B Ratio | 0.25 | 1.47 | 1.93 | 2.61 | 3.91 | 15.19 | — |
| P/FCF | 1.13 | 7.19 | — | 31.15 | — | — | — |
| P/OCF | 1.04 | 6.60 | — | 25.22 | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
DocGo Inc.'s enterprise value stands at 0.9x EBITDA, 95% below its 5-year average of 19.5x. The Healthcare sector median is 13.8x, placing the stock at a 93% discount on an enterprise-value basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 0.70 | 0.93 | 1.34 | 2.28 | 10.61 | — |
| EV / EBITDA | 0.92 | 9.69 | 18.34 | 18.23 | 31.83 | — | — |
| EV / EBIT | 1.43 | 14.55 | 38.37 | 27.05 | 35.41 | — | — |
| EV / FCF | — | 6.70 | — | 25.27 | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
DocGo Inc. earns an operating margin of 4.7%. ROE of 6.4% is modest. ROIC of 7.5% represents adequate returns on invested capital.
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Gross Margin | 34.6% | 34.6% | 31.3% | 35.1% | 34.4% | 33.3% | 27.3% |
| Operating Margin | 4.7% | 4.7% | 2.4% | 5.0% | 4.8% | -15.7% | -43.0% |
| Net Profit Margin | 3.2% | 3.2% | 1.1% | 7.9% | 7.4% | -15.3% | -41.8% |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| ROE | 6.4% | 6.4% | 2.3% | 13.7% | 16.2% | -19.6% | -25.5% |
| ROA | 4.2% | 4.2% | 1.6% | 9.8% | 11.6% | -14.3% | -20.0% |
| ROIC | 7.5% | 7.5% | 5.2% | 15.6% | 19.8% | -23.2% | -33.0% |
| ROCE | 8.8% | 8.8% | 4.9% | 8.0% | 9.4% | -17.6% | -22.8% |
Solvency and debt-coverage ratios — lower is generally safer
DocGo Inc. carries a Debt/EBITDA ratio of 1.3x, which is manageable (59% below the sector average of 3.1x). The company holds a net cash position — cash of $89M exceeds total debt of $57M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns. Interest coverage of 13.2x signals virtually no risk of debt distress — earnings comfortably cover interest obligations.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.18 | 0.18 | 0.15 | 0.07 | 0.07 | 0.21 | 0.20 |
| Debt / EBITDA | 1.28 | 1.28 | 1.48 | 0.61 | 0.72 | — | — |
| Net Debt / Equity | — | -0.10 | -0.04 | -0.49 | -0.70 | -0.28 | -0.41 |
| Net Debt / EBITDA | -0.72 | -0.72 | -0.41 | -4.24 | -6.95 | — | — |
| Debt / FCF | — | -0.50 | — | -5.88 | — | — | — |
| Interest Coverage | 13.24 | 13.24 | — | — | 20.13 | -72.12 | — |
Net cash position: cash ($89M) exceeds total debt ($57M)
Short-term solvency ratios and asset-utilisation metrics
DocGo Inc.'s current ratio of 2.50x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 2.71x to 2.50x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Current Ratio | 2.50 | 2.50 | 1.99 | 2.71 | 4.42 | 2.49 | 6.08 |
| Quick Ratio | 2.50 | 2.50 | 1.99 | 2.66 | 4.42 | 2.49 | 6.08 |
| Cash Ratio | 0.73 | 0.73 | 0.35 | 1.57 | 3.03 | 1.38 | 4.91 |
| Asset Turnover | — | 1.35 | 1.27 | 1.12 | 1.03 | 0.94 | 0.48 |
| Inventory Turnover | — | — | — | 63.79 | — | — | — |
| Days Sales Outstanding | — | 124.85 | 153.23 | 85.34 | 89.77 | 96.42 | 76.80 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
DocGo Inc. returns 100.0% to shareholders annually — split between a 100.0% dividend yield and 18.8% buyback yield. The payout ratio exceeds 100% at 6474653.6%, meaning the company is paying out more than it earns — this level is unsustainable long-term without earnings recovery. The earnings yield of 25.1% (inverse of P/E) provides a useful comparison to bond yields when assessing the stock's relative attractiveness to fixed income.
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Dividend Yield | 100.0% | 100.0% | — | — | — | — | — |
| Payout Ratio | 6474653.6% | 6474653.6% | — | — | — | — | — |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Earnings Yield | 25.1% | 4.2% | 1.2% | 4.8% | 2.7% | — | — |
| FCF Yield | 88.1% | 13.9% | — | 3.2% | — | — | — |
| Buyback Yield | 18.8% | 3.0% | 0.0% | 0.5% | 0.1% | 0.0% | — |
| Total Shareholder Yield | 100.0% | 100.0% | 0.0% | 0.5% | 0.1% | 0.0% | — |
| Shares Outstanding | — | $109M | $106M | $103M | $95M | $100M | $100M |
Compare DCGO with 5 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
| DCGOYou | $73M | 4.0 | 0.9 | 1.1 | 34.6% | 4.7% | 6.4% | 7.5% | 1.3 |
| CHE | $6B | 22.3 | 17.3 | 17.8 | — | 13.4% | 25.3% | 23.8% | 0.4 |
| OPCH | $5B | 25.4 | 12.0 | 19.7 | 19.3% | 6.0% | 15.2% | 15.3% | — |
| ADUS | $2B | 19.9 | 13.2 | — | 32.5% | 9.7% | 9.3% | 8.8% | 1.3 |
| AVAH | $2B | -129.8 | 17.3 | 58.2 | 31.4% | 6.9% | — | 8.0% | 8.8 |
| EHAB | $686M | -4.4 | — | 14.5 | 48.7% | -11.1% | -24.9% | -7.3% | — |
| Healthcare Median | — | 23.7 | 13.8 | 18.8 | 65.8% | -6.3% | -37.3% | -15.0% | 3.1 |
Peers based on L4 peer group classification. Compare multiple stocks →
Includes 30+ ratios · 6 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how DCGO stacks up against sector leader Chemed Corporation.
Start ComparisonDocGo Inc.'s current P/E ratio is 4.0x. The historical average is 42.0x.
DocGo Inc.'s current EV/EBITDA is 0.9x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 19.5x.
DocGo Inc.'s return on equity (ROE) is 6.4%. The historical average is -1.1%.
Based on historical data, DocGo Inc. is trading at a P/E of 4.0x. Compare with industry peers and growth rates for a complete picture.
DocGo Inc.'s current dividend yield is 100.00% with a payout ratio of 6474653.6%.
DocGo Inc. has 34.6% gross margin and 4.7% operating margin.
DocGo Inc.'s Debt/EBITDA ratio is 1.3x, indicating moderate leverage. A ratio below 2x is generally considered financially healthy.